NEWOMICS INC. — Department of Health and Human Services SBIR Phase II: R

Description

DESCRIPTION provided by applicant Natural products are rich sources for potential drugs To accelerate drug discovery from natural products it is imperative to identify their molecular targets and mechanistically elucidate their bioavailability toxicity and therapeutic effects However there remain several challenges in the field Among them there is currently no technical platform that could perform mechanistic studies from the andquot hitsandquot to andquot leadsandquot using the small volumes of samples that are typically encountered in quantitative high throughput screening or obtained from biological and clinical studies To tackle these challenges and in response to RFA AT Newomics Inc proposes to complete development of its product a multiomics platform for high throughput and high content bioassays of natural products The Phase II project is built upon the promising results generated from our Phase I project In Phase I we have developed ESI MS assays to screen the interactions between molecular targets and natural products from libraries with different complexity In Phase II we will complete development of multiomics assays for commercialization through working closely with industry partners academic collaborators and business consultants Once developed Newomicsandapos Omics chip may become a universal platform for high throughput identification of molecular targets of natural products in the blood or other tissues and lay a new foundation for drug discovery and development PUBLIC HEALTH RELEVANCE Cutting edge technologies enable breakthroughs in biomedical research Developments of innovative and integrated mass spectrometry based microfluidic chips will accelerate the high throughput identification and validation of molecular targets of natural products thereby contributing to new drug discovery and development